Illumina (NASDAQ:ILMN) Updates FY 2020 After-Hours Earnings Guidance

Illumina (NASDAQ:ILMN) issued an update on its FY 2020
After-Hours earnings guidance on Monday morning. The company provided earnings per share guidance of 6.80-7.00 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.06. The company issued revenue guidance of $3.86-3.93 billion, compared to the consensus revenue estimate of $3.96 billion.Illumina also updated its FY 2019
After-Hours guidance to EPS.

ILMN stock traded down $12.38 during midday trading on Monday, hitting $323.15. The stock had a trading volume of 2,338,788 shares, compared to its average volume of 1,065,298. The firm has a market cap of $49.32 billion, a price-to-earnings ratio of 56.49, a price-to-earnings-growth ratio of 2.26 and a beta of 1.05. The business has a 50-day moving average of $325.78 and a two-hundred day moving average of $310.67. Illumina has a 52-week low of $263.30 and a 52-week high of $380.76. The company has a debt-to-equity ratio of 0.41, a current ratio of 6.82 and a quick ratio of 6.15.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, October 24th. The life sciences company reported $1.93 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.40 by $0.53. The company had revenue of $907.00 million for the quarter, compared to analysts’ expectations of $872.65 million. Illumina had a return on equity of 22.05% and a net margin of 28.14%. The firm’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same period in the prior year, the firm earned $1.52 earnings per share. Research analysts predict that Illumina will post 6.45 earnings per share for the current year.

ILMN has been the topic of several recent research reports. Wolfe Research set a $380.00 price target on Illumina and gave the stock a buy rating in a research note on Friday, October 25th. Argus upped their price target on Illumina from $300.00 to $340.00 and gave the stock a buy rating in a research note on Wednesday, September 25th. UBS Group raised Illumina from a neutral rating to a buy rating and set a $355.00 price target on the stock in a research note on Friday, January 3rd. Piper Sandler upped their price target on Illumina from $341.00 to $370.00 and gave the stock an overweight rating in a research note on Thursday. Finally, ValuEngine cut Illumina from a buy rating to a hold rating in a research note on Friday, December 20th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Illumina presently has an average rating of Buy and an average target price of $340.69.

In other news, SVP Oene Mark Van sold 625 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $330.99, for a total value of $206,868.75. Following the sale, the senior vice president now directly owns 11,578 shares of the company’s stock, valued at $3,832,202.22. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Susan H. Tousi sold 200 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $325.00, for a total value of $65,000.00. Following the completion of the sale, the senior vice president now directly owns 38,465 shares in the company, valued at $12,501,125. The disclosure for this sale can be found here. Over the last three months, insiders sold 7,920 shares of company stock worth $2,505,932. Insiders own 0.38% of the company’s stock.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Featured Article: Pattern Day Trader – What is the PDT Rule?

Earnings History and Estimates for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply